Booster vaccination against diphtheria, tetanus & pertussis for individuals from ≥4 yr. Passive protection against pertussis in early infancy following maternal immunisation during pregnancy. Management of tetanus prone injuries in persons who have previously received primary vaccination series.
Deep IM 0.5 mL as a single dose in deltoid region. Pregnant women Can be administered during 2nd or 3rd trimester in accordance w/ official recommendations. Adult & adolescent w/ unknown or incomplete vaccination status 2 additional doses at 1 & 6 mth after 1st dose is recommended. Repeat vaccination Perform intervals in accordance w/ official recommendations (generally 10 yr).
View Boostrix overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity or to subjects showing signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines. Encephalopathy of unknown etiology occurring w/in 7 days following previous pertussis-containing vaccination. Transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria &/or tetanus.
Do not administer IV. Postpone vaccination in subjects suffering from acute severe febrile illness. Subsequent dose of vaccine should be carefully considered if any of the following occur: Temp ≥40°C w/in 48 hr of unidentifiable cause; collapse or shock-like state (hypotonic-hyporesponsive episode) w/in 48 hr of vaccination; persistent, inconsolable crying lasting ≥3 hr w/in 48 hr of vaccination; convulsion w/ or w/o fever w/in 3 days of vaccination. Progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Thrombocytopenia or bleeding disorders (in accordance w/ official recommendations, vaccine may need to be administered subcutaneously). Immunosuppressed patients. Syncope may occur. Pregnancy & lactation.
Sign Out
